Case Study: Life Sciences - Future50

9 neuroscience biotech companies you should know about

MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's

Case Study: R&D grant funding

Parkinson’s disease drug hunters think outside the α-synuclein box

NRG raises Series A funds for Parkinson’s and ALS therapy development

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

NRG announces £16m Series A for IND for Parkinson’s and ALS

Following the path to a new drug, together

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS

Omega Funds leads £16m Series A round for NRG Therapeutics

NRG closes £16M series A to fund fight against neurodegenerative diseases

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup

NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

NRG Therapeutics to develop small molecule disease-modifying medicines for debilitating chronic neurodegenerative disorders

£2.68M Award to NRG Therapeutics Supports Work Into Potential DMT

Award to help NRG Therapeutics develop new Parkinson’s and Motor Neurone Disease treatments

NRG receives £2.68m funding boost for neurodegenerative disorders

Sticking plaster for brain could beat Parkinson’s disease

NRG Therapeutics awarded £2.68m to fight Parkinson’s and MND

NRG gearing up for series A to advance brain-penetrant PTP inhibitors

Parkinson’s UK takes investment in NRG Therapeutics to £2.5m

Cambridge neuroscience specialist NRG Therapeutics secures $500,000 from The Michael J Fox Foundation for Parkinson’s Research